Modulators of peroxisome proliferator activated receptors
    22.
    发明授权
    Modulators of peroxisome proliferator activated receptors 失效
    过氧化物酶体增殖物激活受体的调节剂

    公开(公告)号:US06417212B1

    公开(公告)日:2002-07-09

    申请号:US09644457

    申请日:2000-08-23

    IPC分类号: C07D26336

    摘要: The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO2; R1 is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R2 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R3 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R4 are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R5 are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R5 is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and R6 is H, a C1-C4 alkyl, or an aminoalkyl.

    摘要翻译: 本发明涉及由结构式I表示的化合物及其药学上可接受的盐,溶剂合物和水合物及其制备方法,使用方法和具有由结构式I表示的化合物的药物组合物及其药学上可接受的盐,溶剂化物和水合物: 在结构式I中,n为2,3或4; V为O或S; W是O,S或SO 2; R1是H,C1-C4烷基,苯基或三氟甲基; R 2各自独立地为H,C 1 -C 6烷基,芳基-C 1 -C 6烷基,环烷基-C 1 -C 4烷基,芳基,环烷基,或与它们所连接的苯基一起形成萘基或1 ,2,3,4-四氢萘基; R 3各自独立地为H,C 1 -C 6烷基,芳基-C 1 -C 6烷基,环烷基-C 1 -C 4烷基,芳基或环烷基; R 4各自独立地为H,C 1 -C 4烷基,芳基或苄基; R5各自独立地为H,取代或未取代的芳基或杂芳基,条件是至少一个R 5为取代或未取代的芳基或取代或未取代的杂芳基; 并且R 6是H,C 1 -C 4烷基或氨基烷基。

    Modulators of peroxisome proliferator activated receptors
    25.
    发明授权
    Modulators of peroxisome proliferator activated receptors 失效
    过氧化物酶体增殖物激活受体的调节剂

    公开(公告)号:US06825222B2

    公开(公告)日:2004-11-30

    申请号:US10434425

    申请日:2003-05-07

    IPC分类号: A61K31425

    摘要: The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO2; R1 is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R2 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R3 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R4 are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R5 are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R5 is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and R6 is H, a C1-C4 alkyl, or an aminoalkyl.

    摘要翻译: 本发明涉及由结构式I表示的化合物及其药学上可接受的盐,溶剂合物和水合物及其制备方法,使用方法和具有由结构式I表示的化合物的药物组合物及其药学上可接受的盐,溶剂化物和水合物: 在结构式Ⅰ中,n为2,3或4; V为O或S; W是O,S或SO 2; R1是H,C1-C4烷基,苯基或三氟甲基; R 2各自独立地为H,C 1 -C 6烷基,芳基-C 1 -C 6烷基,环烷基-C 1 -C 4烷基,芳基,环烷基,或与它们所连接的苯基一起形成萘基或1 ,2,3,4-四氢萘基; R 3各自独立地为H,C 1 -C 6烷基,芳基-C 1 -C 6烷基,环烷基-C 1 -C 4烷基,芳基或环烷基; R 4各自独立地为H,C 1 -C 4烷基,芳基或苄基; R5各自独立地为H,取代或未取代的芳基或杂芳基,条件是至少一个R 5为取代或未取代的芳基或取代或未取代的杂芳基; 并且R 6是H,C 1 -C 4烷基或氨基烷基。